Literature DB >> 16686669

Contribution of protons to post-ischemic Na(+) and Ca(2+) overload and left ventricular mechanical dysfunction.

Alexander S Clanachan1.   

Abstract

The intracellular accumulation of Na(+) and Ca(2+) plays a key role in ischemia-induced myocardial injury that may be manifest as left ventricular (LV) mechanical dysfunction, dysrhythmias, or infarction. This review considers the potential contributions of protons (H(+)) produced during ischemia as well as reperfusion to intracellular Na(+) and Ca(2+) homeostasis. ATP hydrolysis produces H(+) and the resulting intracellular acidosis directly impairs LV contractility. However, it is the accumulation of intracellular H(+) and the activation of Na(+)-dependent pH regulatory mechanisms, including the Na(+)-H(+) exchanger (NHE-1) and the Na(+)-HCO(3) (-) cotransporter, which contribute to Na(+) accumulation. Intracellular Na(+) accumulation, coupled with the NHE-1, then causes Ca(2+) overload and further LV mechanical dysfunction. As glycolysis uncoupled from glucose oxidation is an important determinant of the rate of H(+) production, factors that affect glucose metabolism, including degree of ischemia, myocardial workload, and competition from other energy substrates, are expected to influence Na(+) and Ca(2+) accumulation, and hence the recovery of post-ischemic LV mechanical function. Whereas an increase in the uncoupling of glycolysis from glucose oxidation accelerates H(+) production and worsens the recovery of LV mechanical function, inhibition of H(+) production improves recovery of post-ischemic LV mechanical function. Thus, alteration of glucose metabolism, either by inhibition of an excessive rate of glycolysis or by stimulation of glucose oxidation, is an attractive drug target to reduce H(+) production and limit Na(+) and Ca(2+) accumulation and thereby prevent post-ischemic LV dysfunction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16686669     DOI: 10.1111/j.1540-8167.2006.00395.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  7 in total

1.  Nav 1.5 mutations linked to dilated cardiomyopathy phenotypes: Is the gating pore current the missing link?

Authors:  Pascal Gosselin-Badaroudine; Adrien Moreau; Mohamed Chahine
Journal:  Channels (Austin)       Date:  2013-12-03       Impact factor: 2.581

2.  Proton-dependent inhibition of the cardiac sodium channel Nav1.5 by ranolazine.

Authors:  S Sokolov; C H Peters; S Rajamani; P C Ruben
Journal:  Front Pharmacol       Date:  2013-06-21       Impact factor: 5.810

3.  Temperature preconditioning is optimal at 26° C and confers additional protection to hypothermic cardioplegic ischemic arrest.

Authors:  Igor Khaliulin; Andrew P Halestrap; M-Saadeh Suleiman
Journal:  Exp Biol Med (Maywood)       Date:  2011-05-23

4.  The role of Na+/H+ exchanger in Ca2+ overload and ischemic myocardial damage in hearts from type 2 diabetic db/db mice.

Authors:  Ryuko Anzawa; Shingo Seki; Tomohisa Nagoshi; Ikuo Taniguchi; Danielle Feuvray; Michihiro Yoshimura
Journal:  Cardiovasc Diabetol       Date:  2012-04-11       Impact factor: 9.951

5.  Cardiac STAT3 Deficiency Impairs Contractility and Metabolic Homeostasis in Hypertension.

Authors:  Raffaele Altara; Romain Harmancey; Sean P Didion; George W Booz; Fouad A Zouein
Journal:  Front Pharmacol       Date:  2016-11-16       Impact factor: 5.810

6.  Olesoxime Inhibits Cardioplegia-Induced Ischemia/Reperfusion Injury. A Study in Langendorff-Perfused Rabbit Hearts.

Authors:  Aida Salameh; Maren Keller; Ingo Dähnert; Stefan Dhein
Journal:  Front Physiol       Date:  2017-05-19       Impact factor: 4.566

Review 7.  Cardiac metabolism as a driver and therapeutic target of myocardial infarction.

Authors:  Coert J Zuurbier; Luc Bertrand; Christoph R Beauloye; Ioanna Andreadou; Marisol Ruiz-Meana; Nichlas R Jespersen; Duvaraka Kula-Alwar; Hiran A Prag; Hans Eric Botker; Maija Dambrova; Christophe Montessuit; Tuuli Kaambre; Edgars Liepinsh; Paul S Brookes; Thomas Krieg
Journal:  J Cell Mol Med       Date:  2020-05-08       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.